Cancer DiscovJClub
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.
Cancer Discovery · · Journal Article
Haldar, Huff + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
A peptide vaccine targeting six mutant KRAS mutations (mKRAS-VAX) generated durable mKRAS-specific T cell responses in 18/20 high-risk hereditary PDAC participants, with no PDAC detected over 16.5 months.
- Why it matters: PDAC develops from precursor lesions over a decade, but current surveillance detects only a minority of precursors, leaving a need for immune-based interception in high-risk individuals.
- What they did: In a phase I first-in-human trial (NCT05013216), 20 participants with hereditary PDAC predisposition and a radiographic pancreatic abnormality received mKRAS-VAX; safety, immunogenicity, and T cell persistence were assessed.
- The result: Adverse events were grade 1–2, mKRAS-specific T cell responses occurred in 18/20 (90%), vaccine-induced clonotypes persisted up to 2 years, and no participants developed PDAC over a median 16.5 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 6 cites